KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2025)

Rigel Pharmaceuticals has reported Non-Current Debt over the past 7 years, most recently at $52.3 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $52.3 million for Q4 2025, changed 0.22% from a year ago — trailing twelve months through Dec 2025 was $52.3 million (changed 0.22% YoY), and the annual figure for FY2025 was $52.3 million, changed 0.22%.
  • Non-Current Debt for Q4 2025 was $52.3 million at Rigel Pharmaceuticals, up from $30.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for RIGL hit a ceiling of $59.8 million in Q3 2024 and a floor of $19.8 million in Q1 2021.
  • Median Non-Current Debt over the past 5 years was $42.2 million (2022), compared with a mean of $41.5 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 101.89% in 2021 and later crashed 49.85% in 2025.
  • Rigel Pharmaceuticals' Non-Current Debt stood at $19.9 million in 2021, then soared by 98.09% to $39.4 million in 2022, then surged by 32.76% to $52.4 million in 2023, then grew by 0.07% to $52.4 million in 2024, then dropped by 0.22% to $52.3 million in 2025.
  • The last three reported values for Non-Current Debt were $52.3 million (Q4 2025), $30.0 million (Q3 2025), and $37.5 million (Q2 2025) per Business Quant data.